

****Published January 2016****

MarketVIEW: Hepatitis B Virus (HBV) vaccines (CAT: VAMV033)

Product Name	:	MarketVIEW: Hepatitis B Virus (HBV) vaccines
Description	:	Global vaccine commercial opportunity assessment
Contents	:	Executive presentation (.pdf) + 2 forecast models (.xls)
Therapeutic Area	:	Existing/mature vaccines
Publication date	:	January 2016
Catalogue No	:	VAMV033

Background

Hepatitis B Virus (HBV) is transmitted by exposure to infectious blood or body fluids by percutaneous or mucosal means. Transmission occurs usually amongst adults exhibiting risk behaviours e.g. IDUs, MSM and heterosexuals with multiple partners although vertical transmission can occur from mother to child at birth. The HBV virus is more infectious than HIV and can cause chronic infection, resulting in cirrhosis of the liver, liver cancer, liver failure, and death. It is estimated that 2 billion people worldwide have been infected with the virus and about 600 000 people die every year due to the consequences of hepatitis B (WHO Figures).

The Hepatitis B vaccine is the mainstay of HBV prevention where the WHO recommends all infants receive the vaccine. As of July 2011, 179 countries vaccinate infants against hepatitis B as part of their vaccination schedules (WHO Figures). People in high-risk groups are also recommended although policies vary widely from country to country.

This **MarketVIEW** product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Hepatitis B Virus (HBV) adult vaccines across major Western¹ markets until 2030. The model contains value (\$ m) and volume (mio doses) predictions per product type along with timeframe, pricing and penetration estimates for all adult risk groups and infants vaccination (where policy in place). The product also includes two different scenarios for the potential penetration of Dynavax's new HBV vaccine **Heplisav** into US and EU markets and giving estimates of potential revenues to 2030.

¹ US, Canada, Australia, UK, France, Italy, Germany, Spain

Methodology

VacZine Analytics has closely monitored all significant source material pertaining Hepatitis B Virus (HBV) epidemiology, disease indications and target groups. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by **VacZine Analytics** in the field of viral pathogens has also been utilised.

PRODUCT CONTENTS:

Published January 2016 (CAT No: VAMV033)

****This product is composed of two models (.xls) and summary presentation (.pdf)

Author's note
Contents
Executive Summary
Commercial model: outputs
General summary of changes from versions 2013 to 2015
HBV vaccines: revenues by vaccine type to 2030 (Western) (\$m)
HBV vaccines: revenues by vaccine type to 2030 (per country) (\$m)
Monovalent HBV vaccines: revenues to 2030 (per country) (\$m)
Monovalent HBV vaccines: revenues to 2030 (per risk group) (\$m)
Hepilisav: market revenues to 2030 (\$m) – SCENARIO 1
Hepilisav: market revenues to 2030 (\$m) – SCENARIO 2
Hepatitis B virus background: Epidemiology update
HBV: epidemiology summary
HBV: global epidemiology
HBV: global prevalence of chronic infection
Characteristics of hepatitis B in US
US: HBV incident cases and risk exposures (2012)
Reported number of acute HBV cases - US, 2000-2012
US: HBV incident cases and risk exposures 1980-2010
Acute HBV reports by risk exposure (US, 2012)
US - HBV surface antigen positivity by state, 2009
Europe: HBV epidemiology
Europe: number of reported HBV cases in the EU/EEA, 2012
Number and rates of HBV reported cases, EU/EEA, 2009-2012
Europe: HBV cases - by age group & gender EU/EEA (2011)
Hepatitis B virus background: vaccines
Reimbursement policies: per major risk group/country
Vaccine market share split per country
At risk populations per country
HBV vaccine coverage by country
HBV background
HBV epidemiology summary
HBV global epidemiology
US: incident cases and risk exposures

Continued.....

National HBV vaccine policies
National HBV vaccine policies: forecast immunity to 2030
Hepatitis B vaccines: major suppliers
Hepatitis B vaccines: dosing/administration schedules
GSK Biologicals: hepatitis vaccine sales, 2005-14
Merck & Co (SPMSD): hepatitis vaccine sales, 2005-14
Engerix B: SWOT
Recombivax-HB: SWOT
New Hepatitis B vaccines: Heplisav (Dynavax)
Dynavax: Heplisav – background
Heplisav: Phase III data
Heplisav: seroprotection rates (HBV-16) study
Heplisav: immunogenicity in diabetic subjects
Heplisav: FDA - Complete Response Letter
Heplisav: HBV-23 study
Heplisav: approval timeframe (US)
VBI vaccines: Sci-B-Vac
HBV vaccines: commercial model: key assumptions and methodology
Overview of modeling strategy
Target populations modelled
HBV vaccines: target populations (US, 2015) (000s)
Healthcare workers: modeling strategy
Travelers: modeling strategy
Diabetics: modeling strategy, US
Infants: modeling strategy
Other “at risk” populations: modelling strategy
Summary of population changes from version 2013 - 2015
Pricing and reimbursement
Pricing assumptions
Market share split by country: by vaccine type
At risk populations by country
HBV vaccine coverage by country
HBV vaccination in US diabetics 2010-2013
Heplisav: market share/pricing estimates
Heplisav: expected commercial value US
Appendix I: Actual reported and estimated sales data
Hepatitis vaccines sales data
Bibliography
About **VacZine Analytics**
Disclaimer

PAGES: ~74 fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand models (MS Excel-based)

Title sheet
CHARTS – VALUE
CHARTS – VOLUME
Heplisav sales forecast

Continued.....

Country value summary
Value adults (all)
Value adults (monovalent)
Value (Twinrix)
Volume
Adult worksheets →
US (adults)
Canada (adults)
Australia (adults)
France (adults)
Germany (adults)
Italy (adults)
Spain (adults)
UK (adults)
Spain (adults)
Adult worksheets →
US (infants)
Canada (infants)
Australia (infants)
Europe universal (infants)
Europe at risk (infants)
Source material →
Births
Total populations
18-49 yrs
Global price summary
At risk variables
Public/private split
Monovalent combi split
ESRD incidence forecast
ESRD incident cases 2014 report
ESRD incidence rate 2014 report
Trips to HBV endemic countries
Travel market variables
HBV cases US
HBV cases US by risk group
HBV cases US
Diabetes
Pneumo vaccine coverage
Sales data
Sales charts
Back page

Worksheets = 65 interconnected

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- USD \$9995.00/ GBP £6535.00# (Region license)*

*A region is North America, Europe or ROW

For orders in the UK, VAT at 20% will be added to final invoice total

- *indicative prevailing rate will be applied on date of transaction*

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY

1. WHO. Weekly epidemiological record. 11 November 2011, 86th. No. 46, 2011, 86, 509–520
2. CDC. Traveler's health; yellow book. Atlanta, GA: US Department of Health and Human Services, CDC; 2008.
3. US Centers for Disease Control and Prevention. Hepatitis B Information for Health Professionals. Available at: <http://www.cdc.gov/hepatitis/Statistics/2012Surveillance/Commentary.htm#hepB>. Accessed February 2015
4. US Centers for Disease Control and Prevention. Viral Hepatitis Statistics and Surveillance. Available at: <http://www.cdc.gov/hepatitis/Statistics/2012Surveillance/Slide3.1.htm> Accessed February 2015
5. US Centers for Disease Control and Prevention. Hepatitis B Information for Health Professionals. Available at: <http://www.cdc.gov/hepatitis/HBV/HBVfaq.htm#overview>. Accessed February 2015
6. US Centers for Disease Control and Prevention. Viral Statistics and Surveillance. Available at: <http://www.cdc.gov/hepatitis/Statistics/2012Surveillance/Slide3.6b.htm>. Accessed February 2015
7. Hepatitis B virus. LabCorp. Laboratory Corporation of America. Available at: www.labcorp.com. Accessed February 2015
8. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2013. Available at: <http://www.ecdc.europa.eu/en/publications/Publications/annual-epidemiological-report-2013.pdf>. Accessed February 2015
9. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2014. Available at: <http://www.ecdc.europa.eu/en/publications/Publications/annual-epidemiological-report-2014.pdf>. Accessed February 2015
10. ECDC. Vaccination schedules. Available at: <http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx>. Accessed: February 2015
11. HEPLISAV Hepatitis B vaccine. Available at: <http://www.dynavax.com/our-pipeline/adjuvants/heplisav-b/>. Accessed: February 2015.
12. FDA Briefing Document. Vaccines and Related Biological Products Advisory Committee Meeting November 15, 2012.
13. WHO. Hepatitis B. Available at: <http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index4.html>. Accessed: February 2015.
14. Dynavax Technologies Corporation. Vaccine and Related Biological Products Advisory Committee HEPLISAV BLA #125428. November 15, 2012.
15. Heyward WL et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age. *Vaccine*. 2013 Nov 4;31(46):5300-5.
16. Dynavax Corporate Presentation. 33rd Annual JP Morgan Healthcare Conference. January 2015.
17. De Schryver A et al. European survey of hepatitis B vaccination policies for healthcare workers. *Eur J Public Health*. 2011 Jun;21(3):338-43.
18. Georgetown University Center on Education and the Workforce. Healthcare. Available at: <http://cew.georgetown.edu/healthcare/>. Accessed February 2015
19. World Tourism Organisation (WTO). Available at: <http://www.e-unwto.org>. Accessed December 2012. Data held at VacZine Analytics
20. Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep*. 2011 Dec 23;60(50):1709-11.
21. US Centres for Disease Control and Prevention. National diabetes statistics report, 2014. Available at: <http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf>. Accessed February 2015
22. Creating public awareness: State 2025 diabetes forecasts. *Population Health Management*. (2012) Volume 15. Number 4
23. *MMWR*. Adult Vaccination Coverage — United States, 2012. February 7, 2014 / 63(05);95-102.
24. Percentage of Adults Aged 18 Years or Older with Diagnosed Diabetes Ever Receiving a Pneumococcal Vaccination, by Age, United States, 1993–2010. Available at: <http://www.cdc.gov/diabetes/statistics/preventive/tPneumAgeTot.htm>. Accessed: February 2015.
25. US Centres for Disease Control and Prevention. HIV among gay and bisexual men. Available at: <http://www.cdc.gov/hiv/risk/gender/msm/facts/index.html>. Accessed February 2015
26. Miriti MK et al. Economic benefits of hepatitis B vaccination at sexually transmitted disease clinics in the U.S. *Public Health Rep*. 2008 Jul-Aug;123(4):504-13.
27. Zimmerman R et al. Integrating viral hepatitis prevention into STD clinics in Illinois (excluding Chicago), 1999-2005. *Public Health Rep*. 2007;122 Suppl 2:18-23
28. Harris JL et al. Hepatitis B Vaccination in Six STD Clinics in the United States Committed to Integrating Viral Hepatitis Prevention Services. *Public Health Rep*. 2007; 122(Suppl 2): 42–47.

29. Mathers BM et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. *Lancet*. 2008 Nov 15;372(9651):1733-45.
30. 2014 USRDS Annual Data Report. Volume Two: End Stage Renal Disease in the United States. Incidence & Prevalence. Available at: <http://www.usrds.org/> Accessed February 2015
31. Collins AJ et al. Overview of the ESRD Program. Trends projected growth and infectious hospitalizations. Available at: http://www.usrds.org/2011/pres/USRDS2hrtalk/USRDS_2011_ASN_talk_AC.pdf. Accessed February 2015
32. Bel'eed K et al. Vaccination against hepatitis B infection in patients with end stage renal disease. *Postgrad Med J*. 2002 Sep;78(923):538-40.
33. Chaves SS. Et al. Immunogenicity of hepatitis B vaccine among hemodialysis patients: effect of revaccination of non-responders and duration of protection. *Vaccine*. 2011 Dec 6;29(52):9618-23.

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according to the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. **Force Majeure:** The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009

Follow us on Twitter [@vaczineanalytic](https://twitter.com/vaczineanalytic)

